Mangoceuticals
MGRX
11 hedge funds and large institutions have $820K invested in Mangoceuticals in 2025 Q3 according to their latest regulatory filings, with 4 funds opening new positions, 3 increasing their positions, 1 reducing their positions, and 3 closing their positions.
200% more repeat investments, than reductions
Existing positions increased: 3 | Existing positions reduced: 1
85% more capital invested
Capital invested by funds: $444K → $820K (+$376K)
33% more first-time investments, than exits
New positions opened: 4 | Existing positions closed: 3
10% more funds holding
Funds holding: 10 → 11 (+1)
2.65% less ownership
Funds ownership: 2.65% → 0% (-2.6%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Geode Capital Management
Boston,
Massachusetts
|
+$115K |
| 2 |
XT
XTX Topco
George Town,
Cayman Islands
|
+$53.1K |
| 3 |
Northern Trust
Chicago,
Illinois
|
+$35.3K |
| 4 |
Vanguard Group
Malvern,
Pennsylvania
|
+$17.5K |
| 5 |
SS
Sunbelt Securities
Houston,
Texas
|
+$13K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Renaissance Technologies
New York
|
-$47.1K |
| 2 |
Goldman Sachs
New York
|
-$16.1K |
| 3 |
TRCT
Tower Research Capital (TRC)
New York
|
-$2.81K |
| 4 |
UBS Group
Zurich,
Switzerland
|
-$142 |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
1
Vanguard Group
Malvern,
Pennsylvania
| $420K | +$17.5K | +9,391 | +5% |
|
|
2
Geode Capital Management
Boston,
Massachusetts
| $193K | +$115K | +61,476 | +232% |
|
|
ACA
3
Ackerman Capital Advisors
Dallas,
Texas
| $75.6K | – | – | – |
|
|
XT
4
XTX Topco
George Town,
Cayman Islands
| $62.4K | +$53.1K | +28,514 | New |
|
|
5
Northern Trust
Chicago,
Illinois
| $41.5K | +$35.3K | +18,957 | New |
|
|
SS
6
Sunbelt Securities
Houston,
Texas
| $15.3K | +$13K | +7,000 | New |
|
7
Osaic Holdings
Scottsdale,
Arizona
| $6.09K | – | – | – |
|
|
SPIA
8
Steward Partners Investment Advisory
New York
| $4.59K | – | – | – |
|
9
Royal Bank of Canada
Toronto,
Ontario, Canada
| $1K | +$840 | +451 | New |
|
10
Bank of America
Charlotte,
North Carolina
| $386 | +$24 | +13 | +8% |
|
|
11
UBS Group
Zurich,
Switzerland
| $7 | -$142 | -76 | -96% |
|
|
12
Renaissance Technologies
New York
| – | -$47.1K | -31,000 | Closed |
|
|
13
Goldman Sachs
New York
| – | -$16.1K | -10,570 | Closed |
|
|
TRCT
14
Tower Research Capital (TRC)
New York
| – | -$2.81K | -1,850 | Closed |
|
MGRX Hedge Fund Activity: Q3 2025 in Review
11 of the 7,629 institutional investors tracked by Wall St. Rank reported a position in Mangoceuticals (MGRX) for Q3 2025, worth a combined $820K — up 85% from $444K a quarter earlier.
Buyers outnumbered sellers: 4 funds opened new MGRX positions and 3 closed out — a net gain of 1 holder — while 3 added to existing stakes and 1 trimmed.
The largest buyer was Geode Capital Management, adding an estimated $115K. The largest seller was Renaissance Technologies, exiting entirely with an estimated $47.1K sold.
- 11 institutional investors held Mangoceuticals (MGRX) as of Q3 2025, up from 10 in Q2 2025.
- Funds reported $820K of Mangoceuticals stock for Q3 2025, up 85% quarter-over-quarter.
- 4 funds opened new Mangoceuticals positions in Q3 2025 and 3 closed out, a net change of +1 holder.
- The largest Mangoceuticals buyer in Q3 2025 was Geode Capital Management, an estimated $115K added.
- The largest Mangoceuticals seller in Q3 2025 was Renaissance Technologies, an estimated $47.1K sold.
Based on aggregated 13F filings for Q3 2025.